Who Paid My Doc
Elysa Marco
Neurodevelopmental Disabilities San Francisco, CA Medical Doctor
NPI 1518032713 CMS profile 1118193
350 Parnassus Ave, Ste 609, San Francisco, CA 94143
General payments
$10,037
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$651,250
Through program year 2025, Elysa Marco of San Francisco, CA is reported in the CMS Open Payments database as having received $10,037 across 7 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $651,250 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 89th percentile of Neurodevelopmental Disabilities profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $4,787 | 3 | |
| 2023 | General | $500 | 1 | |
| 2022 | General | $4,750 | 3 |
Beside peers
- Elysa Marco
- Neurodevelopmental Disabilities median
- Middle half of Neurodevelopmental Disabilities
- National median
In program year 2025, general payments to Elysa Marco were reported at $4,787. Among 64 Neurodevelopmental Disabilities profiles paid that year, the median was $136 and the middle half received between $67 and $819.
Show as a table
| Year | Elysa Marco | Neurodevelopmental Disabilities median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $138 | $34–$757 | $163 |
| 2020 | $0 | $63 | $23–$471 | $114 |
| 2021 | $0 | $158 | $43–$1,017 | $132 |
| 2022 | $4,750 | $225 | $76–$1,106 | $149 |
| 2023 | $500 | $228 | $73–$994 | $160 |
| 2024 | $0 | $167 | $57–$1,310 | $164 |
| 2025 | $4,787 | $136 | $67–$819 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 7 drugsPart D claims
114
Drug cost
$19,307
Branded share of claims
25.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Valtoco Diazepam | Brand | 12 | $9,939 | |
| Lamotrigine Er Lamotrigine | Brand | 17 | $6,781 | |
| Propranolol Hcl | Generic | 14 | $811 | |
| Olanzapine | Generic | 16 | $741 | |
| Trazodone Hcl | Generic | 24 | $601 | |
| Buspirone Hcl | Generic | 18 | $430 | |
| Clonazepam | Generic | 13 | $6 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.
Records
7 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Neurodevelopmental Disabilities in California
William Shields
Neurodevelopmental Disabilities · Los Angeles, CA
Raman Sankar
Neurodevelopmental Disabilities · Los Angeles, CA
Joyce Wu
Neurodevelopmental Disabilities · Los Angeles, CA
Ying Peng
Neurodevelopmental Disabilities · Ladera Ranch, CA
Jason Lerner
Neurodevelopmental Disabilities · Los Angeles, CA
Christopher Giza
Neurodevelopmental Disabilities · Los Angeles, CA
Related records
Neurodevelopmental Disabilities in California
Practitioners in the same specialty and state, ranked by reported value.
All Neurodevelopmental Disabilities
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.